AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

NASDAQ:AMPH • US03209R1032

28.5 USD
+0.95 (+3.45%)
At close: Feb 13, 2026
28.5 USD
0 (0%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth This makes AMPH very considerable for value investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • AMPH had positive earnings in the past year.
  • AMPH had a positive operating cash flow in the past year.
  • Each year in the past 5 years AMPH has been profitable.
  • AMPH had a positive operating cash flow in each of the past 5 years.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

  • AMPH's Return On Assets of 6.70% is amongst the best of the industry. AMPH outperforms 87.96% of its industry peers.
  • With an excellent Return On Equity value of 14.37%, AMPH belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
  • AMPH has a Return On Invested Capital of 8.51%. This is amongst the best in the industry. AMPH outperforms 86.91% of its industry peers.
  • AMPH had an Average Return On Invested Capital over the past 3 years of 12.92%. This is in line with the industry average of 12.64%.
  • The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 6.7%
ROE 14.37%
ROIC 8.51%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 15.43%, AMPH belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
  • AMPH's Profit Margin has improved in the last couple of years.
  • AMPH has a better Operating Margin (20.73%) than 88.48% of its industry peers.
  • AMPH's Operating Margin has improved in the last couple of years.
  • With a decent Gross Margin value of 49.36%, AMPH is doing good in the industry, outperforming 64.40% of the companies in the same industry.
  • AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 20.73%
PM (TTM) 15.43%
GM 49.36%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
  • The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
  • The number of shares outstanding for AMPH has been increased compared to 5 years ago.
  • The debt/assets ratio for AMPH has been reduced compared to a year ago.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 2.44 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.44, AMPH is doing good in the industry, outperforming 64.40% of the companies in the same industry.
  • AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
  • The Debt to FCF ratio of AMPH (5.49) is better than 83.25% of its industry peers.
  • AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
  • AMPH has a worse Debt to Equity ratio (0.78) than 70.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 5.49
Altman-Z 2.44
ROIC/WACC0.96
WACC8.88%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
  • AMPH has a Current ratio (3.12) which is in line with its industry peers.
  • AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.21, AMPH is in line with its industry, outperforming 46.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.21
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for AMPH have decreased by -9.95% in the last year.
  • Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 61.62% on average per year.
  • Looking at the last year, AMPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
  • AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%

3.2 Future

  • AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.14% yearly.
  • AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.14% yearly.
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • AMPH is valuated reasonably with a Price/Earnings ratio of 8.28.
  • Based on the Price/Earnings ratio, AMPH is valued cheaper than 93.19% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.97. AMPH is valued rather cheaply when compared to this.
  • AMPH is valuated cheaply with a Price/Forward Earnings ratio of 7.67.
  • Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 92.67% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.96. AMPH is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 8.28
Fwd PE 7.67
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaper than 92.15% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AMPH is valued cheaply inside the industry as 90.05% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.8
EV/EBITDA 7.59
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.9%
EPS Next 3Y0.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AMPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (2/13/2026, 8:00:00 PM)

After market: 28.5 0 (0%)

28.5

+0.95 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners74.02%
Inst Owner Change-0.72%
Ins Owners9.38%
Ins Owner Change-0.09%
Market Cap1.31B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target32.2 (12.98%)
Short Float %10.93%
Short Ratio10.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-0.45%
PT rev (3m)-4.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.73%
EPS NY rev (1m)0%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.16%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE 8.28
Fwd PE 7.67
P/S 1.81
P/FCF 11.8
P/OCF 8.6
P/B 1.69
P/tB 6.4
EV/EBITDA 7.59
EPS(TTM)3.44
EY12.07%
EPS(NY)3.71
Fwd EY13.04%
FCF(TTM)2.42
FCFY8.48%
OCF(TTM)3.31
OCFY11.63%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.13
Graham Number36.17
Profitability
Industry RankSector Rank
ROA 6.7%
ROE 14.37%
ROCE 10.26%
ROIC 8.51%
ROICexc 10.49%
ROICexgc 20.29%
OM 20.73%
PM (TTM) 15.43%
GM 49.36%
FCFM 15.35%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 5.49
Debt/EBITDA 3
Cap/Depr 78.19%
Cap/Sales 5.71%
Interest Coverage 6.36
Cash Conversion 75.12%
Profit Quality 99.44%
Current Ratio 3.12
Quick Ratio 2.21
Altman-Z 2.44
F-Score5
WACC8.88%
ROIC/WACC0.96
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.1%
EBIT Next 3Y1.2%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%

AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ

What is the fundamental rating for AMPH stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMPH.


What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?

ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.


Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.


What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 8.28 and the Price/Book (PB) ratio is 1.69.